- Home
- BOOT vs ABVX Comparison
BOOT vs ABVX Comparison
Compare BOOT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- ABVX
- Stock Information
- Founded
- BOOT 1978
- ABVX 2013
- Country
- BOOT United States
- ABVX France
- Employees
- BOOT N/A
- ABVX N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- ABVX
- Sector
- BOOT Consumer Discretionary
- ABVX
- Exchange
- BOOT Nasdaq
- ABVX Nasdaq
- Market Cap
- BOOT 5.1B
- ABVX 5.3B
- IPO Year
- BOOT 2014
- ABVX N/A
- Fundamental
- Price
- BOOT $176.74
- ABVX $84.01
- Analyst Decision
- BOOT Strong Buy
- ABVX Strong Buy
- Analyst Count
- BOOT 13
- ABVX 8
- Target Price
- BOOT $189.77
- ABVX $90.63
- AVG Volume (30 Days)
- BOOT 490.6K
- ABVX 1.2M
- Earning Date
- BOOT 10-27-2025
- ABVX 08-11-2025
- Dividend Yield
- BOOT N/A
- ABVX N/A
- EPS Growth
- BOOT 29.02
- ABVX N/A
- EPS
- BOOT 6.36
- ABVX N/A
- Revenue
- BOOT $1,991,785,000.00
- ABVX $7,073,400.00
- Revenue This Year
- BOOT $15.85
- ABVX $25.23
- Revenue Next Year
- BOOT $13.10
- ABVX N/A
- P/E Ratio
- BOOT $27.79
- ABVX N/A
- Revenue Growth
- BOOT 16.70
- ABVX N/A
- 52 Week Low
- BOOT $86.17
- ABVX $4.77
- 52 Week High
- BOOT $191.31
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- BOOT 49.85
- ABVX 67.94
- Support Level
- BOOT $181.38
- ABVX $82.72
- Resistance Level
- BOOT $189.44
- ABVX $91.30
- Average True Range (ATR)
- BOOT 6.41
- ABVX 3.62
- MACD
- BOOT 0.15
- ABVX -1.13
- Stochastic Oscillator
- BOOT 30.52
- ABVX 47.89
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.